vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $16.01 and traded as low as $13.21. vTv Therapeutics shares last traded at $13.21, with a volume of 6,966 shares.
vTv Therapeutics Stock Performance
The company has a 50 day simple moving average of $16.01 and a two-hundred day simple moving average of $20.43. The company has a market cap of $39.76 million, a PE ratio of -1.49 and a beta of 0.65.
vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.81) EPS for the quarter.
Institutional Investors Weigh In On vTv Therapeutics
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
Recommended Stories
- Five stocks we like better than vTv Therapeutics
- How to Capture the Benefits of Dividend Increases
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Conference Calls and Individual Investors
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What is the Australian Securities Exchange (ASX)
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.